PLSE — Pulse Biosciences Income Statement
0.000.00%
- $977.20m
- $942.32m
- 34
- 15
- 85
- 41
Annual income statement for Pulse Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 1.42 | 0.7 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | -0.55 | -11.2 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 48 | 50 | 64.4 | 58.8 | 43.6 |
Operating Profit | -48 | -50 | -63 | -58.1 | -43.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -47 | -49.9 | -63.7 | -58.5 | -42.2 |
Provision for Income Taxes | |||||
Net Income After Taxes | -47 | -49.9 | -63.7 | -58.5 | -42.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -47 | -49.9 | -63.7 | -58.5 | -42.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -47 | -49.9 | -63.7 | -58.5 | -42.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.26 | -2.14 | -2.28 | -1.7 | -0.877 |